Semaglutide Cost in 2026: With & Without Insurance

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans (full refund on 3-month and 6-month plans) · cancel anytime

At a glance: Semaglutide Cost Options in 2026

Way to get semaglutide	Cost / month (2026)	Notes
Brand Wegovy (list price)	~$1,349	Sticker price; few people pay this
Brand Wegovy (NovoCare self-pay)	~$349 (~$199 intro)	Intro for first 2 fills; verify current offer at NovoCare before deciding
Oral Wegovy pill (self-pay)	~$149	Newer dosage form; also via NovoCare self-pay program
With insurance + savings card	as low as $25	Only if your plan covers weight-loss drugs; commercial insurance only (not Medicare/Medicaid)
Medicare Bridge (CMS, July 2026)	~$50	New program; verify eligibility + drug list on CMS.gov before the program start date
Compounded semaglutide (telehealth)	~$99–$199 all-in	Not FDA-approved; patient-specific preparation; Nouri is $120/mo (6-month plan)

Prices reflect publicly available information as of June 2026 and change frequently — verify current figures directly with the manufacturer, CMS, or your insurer before deciding.

Why does semaglutide cost so much?

Semaglutide's pricing reflects a straightforward market reality: there is no FDA-approved generic, and Novo Nordisk is the only manufacturer of FDA-approved semaglutide products in the US. The main patents on the molecule run to approximately 2032, according to FDA Orange Book data tracked by Drugs.com.

Demand has been steep since the FDA approved semaglutide (Wegovy) for chronic weight management in adults in 2021. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) notes that GLP-1 receptor agonists are among the most effective prescription medications currently available for treating obesity in adults — a condition affecting more than 40% of US adults.

The STEP-1 trial — Novo Nordisk's pivotal study of Wegovy (brand-name semaglutide 2.4 mg) in adults with obesity — found average weight reductions of approximately 15% of body weight versus about 2.4% with placebo over 68 weeks (Wilding et al., NEJM 2021). That clinical profile drives both high demand and the pricing power behind the brand. Note: that trial evaluated Wegovy — a brand-name FDA-approved drug — not compounded semaglutide preparations.

High demand plus a single US supplier equals sustained high prices. Novo Nordisk's own self-pay and patient-assistance programs — and independently prepared compounded versions — are currently the main ways to access semaglutide at lower cost.

Without insurance: the real number is self-pay, not list price

The ~$1,349/month list price for Wegovy is largely a billing artifact at this point. Through Novo Nordisk's NovoCare self-pay program, brand semaglutide (Wegovy injectable) runs about $349/month, with a roughly $199/month introductory price for the first two fills. The oral Wegovy pill — a newer dosage form — is available through the same program for about $149/month.

If you are comparing costs without insurance, use the self-pay program prices as your benchmark, not the list price. The self-pay terms are program-specific and can change; check directly at NovoCare on the day you plan to fill your prescription. As of June 2026, the $199 introductory offer was set to expire around June 30, 2026 — confirm whether it has been extended or replaced.

For a broader comparison of all brand and compounded GLP-1 costs side by side, see our GLP-1 cost guide for 2026.

With insurance: copays and the coverage gap

If your insurance plan covers semaglutide for weight management, a Novo Nordisk manufacturer savings card can bring the copay to as little as $25/month. This applies to commercial (employer or marketplace) insurance plans only; it is not available to Medicare or Medicaid beneficiaries.

The catch: coverage is far from universal. Roughly 40% of employer-sponsored health plans exclude weight-loss drugs from their formularies, according to benefit survey data tracked by GoodRx. Even plans that do cover GLP-1s often require prior authorization and documentation of obesity (BMI ≥30, or ≥27 with a weight-related condition). Check your plan's formulary and prior-authorization requirements before assuming coverage.

Medicare and the new CMS GLP-1 Bridge program

Medicare Part D has historically excluded drugs prescribed solely for weight management. That is changing: CMS announced a Medicare GLP-1 Bridge program offering roughly $50/month access to GLP-1 medications for eligible Medicare beneficiaries, with a target start date of July 1, 2026. Eligibility criteria and the covered drug list are still being finalized — verify current details on the CMS newsroom before relying on this program.

For a full breakdown of what insurance covers and how to navigate prior authorization, see Does insurance cover Wegovy and Zepbound? and how to get a GLP-1 covered by insurance.

Compounded semaglutide: the lower-cost route (and what to know)

Compounded semaglutide from a licensed telehealth provider typically runs $99–$199/month. Before comparing prices, there are several important points to understand:

What compounded semaglutide is — and isn't

Compounded semaglutide is prepared by a state-licensed 503A compounding pharmacy to fill an individual patient's prescription. It contains semaglutide as the active ingredient but is not FDA-approved as a finished drug product. It was not the product studied in Novo Nordisk's STEP trials, and it carries no FDA-reviewed equivalence to Wegovy or Ozempic. The FDA's guidance on human drug compounding provides more background on how 503A pharmacies operate and what oversight applies.

Compounded semaglutide is also not a generic. No FDA-approved generic semaglutide exists. If a provider refers to compounded semaglutide as a "generic" or implies it is the same as, equivalent to, or interchangeable with Wegovy or Ozempic, that claim is not accurate under current FDA standards.

Since the shortage ended: patient-specific requirements

Compounded semaglutide was widely available during the 2022–2024 Wegovy shortage. Following the FDA's shortage resolution, federal compounding rules tightened: 503A pharmacies may now compound semaglutide only for prescriptions that meet genuine patient-specific clinical criteria — for example, a documented allergy to an inactive ingredient in the brand or a specific dose not commercially available. Not every telehealth platform verifies patient-specific eligibility rigorously; if you are considering compounded semaglutide, confirm that a U.S.-licensed physician reviews your intake and makes that determination for your specific case.

Watch for teaser pricing

A "$99/month" headline price at some telehealth platforms adds a separate $49–$79/month membership fee on top. That brings the real all-in cost to $148–$178/month or more. Before comparing providers, ask for the total monthly cost including any membership, consultation, or platform fee. Compare the all-in number, not the headline drug price.

For a detailed side-by-side comparison of compounded versus brand costs and what each includes, see compounded vs. brand GLP-1 cost.

Is there a generic semaglutide?

No. There is no FDA-approved generic semaglutide in the US as of 2026. The primary US patents on the molecule and its key formulation variants run to approximately 2032 — meaning no manufacturer can file for a standard generic approval until those patents expire or are successfully challenged. After patent expiration, an Abbreviated New Drug Application (ANDA) process would still be required before any generic could be sold. Compounded semaglutide is not a generic and is not equivalent to the brand-name products under FDA standards.

Can FSA or HSA funds cover semaglutide?

Compounded semaglutide, when lawfully prescribed by a licensed provider, may be eligible for FSA or HSA reimbursement as a qualified medical expense under IRC §213(d). A few important caveats apply:

• Reimbursement only, not direct card. Compounding pharmacies generally do not participate in IIAS (Inventory Information Approval System) networks, so FSA/HSA debit cards typically will not process at the point of sale. You pay out of pocket, keep your receipt, and submit a reimbursement claim to your benefits administrator.
• Letter of Medical Necessity (LMN). Some plans require a letter from your prescribing physician documenting medical necessity before approving reimbursement for weight-loss medications.
• Plan administrator is the final word. FSA and HSA eligibility rules vary by plan and by how the plan administrator classifies weight-loss versus weight-management medications. Do not assume reimbursement — confirm with your plan administrator before prescribing or purchasing.

For a full guide to GLP-1 FSA and HSA eligibility, see Can you use an HSA or FSA for a GLP-1?. This is general information, not tax or financial advice — consult a tax professional for your specific situation.

How to compare your true out-of-pocket cost

List prices and headline drug prices are both misleading. Here is a practical framework for comparing real costs:

1. Get your insurance formulary status first. Call your insurer or check your online benefits portal. Ask specifically whether semaglutide for weight management (not diabetes) is covered, what tier it sits on, and whether prior authorization is required.
2. Check the manufacturer's self-pay program. If insurance doesn't cover it or the copay is high, check NovoCare's current self-pay terms directly on Wegovy.com — these change periodically.
3. For compounded: ask for the all-in monthly cost. Request the total you will pay per month including any membership, platform, or consultation fee. A provider that shows a clear, single all-in number is easier to compare than one with tiered add-ons.
4. Factor in the full commitment. Some programs lock you into a 3- or 6-month plan. Compare the total dollar commitment, not just the monthly figure, against what you get included.
5. Check the commitment against cancellation terms. Understand what happens if you stop in month two.

Our GLP-1 cost comparison guide breaks down how to do this across all major access routes and platforms.

Where Nouri fits on cost

Nouri's compounded semaglutide is priced at $120/month on the 6-month plan ($720 billed every six months), or $145/month on the 3-month plan. There is also a monthly option at $175/month. Compounded tirzepatide is $175/month on the 6-month plan, $199/month on the 3-month plan, or $225/month billed monthly.

Those are single, all-in prices — no membership fee, no per-dose surcharge, no hidden add-ons. Unlike a prescription-only service, the Nouri program includes a personalized nutrition plan, a movement plan, and concierge care from the Nouri Care Team at one price. Any dose adjustment stays at the same monthly price for that plan tier.

The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Nouri is available in all 50 states. A U.S.-licensed physician reviews your health intake and determines whether compounded GLP-1 medication is clinically appropriate for your specific case — not all applicants qualify. Nouri is LegitScript-certified, and medication is prepared by state-licensed 503A compounding pharmacies (Jungle Jim's Pharmacy, Fairfield, OH; and VialsRX). Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs.

For the underlying pricing dataset that informs this and related cluster articles, see Nouri's GLP-1 telehealth pricing dataset on Hugging Face.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans (full refund on 3-month and 6-month plans) · cancel anytime · all 50 states

Related cost guides

• Pillar: GLP-1 cost in 2026: complete guide
• Ozempic cost without insurance
• Wegovy cost without insurance
• Tirzepatide cost without insurance
• Compounded vs. brand GLP-1 cost
• Can you use an HSA or FSA for a GLP-1?
• Cheapest way to get a GLP-1: cost comparison

Frequently asked questions

How much does semaglutide cost per month without insurance?

As of June 2026, brand semaglutide (Wegovy) self-pay is about $349/month through NovoCare (with a ~$199 introductory price for the first two fills), and the oral Wegovy pill is about $149/month. Compounded semaglutide via telehealth typically runs $99–$199/month all-in; it is not FDA-approved. The $1,349 list price is rarely what people actually pay.

How much does semaglutide cost a month?

It depends on how you access it. Brand self-pay (Wegovy injectable) is about $349/month; the oral Wegovy pill is about $149/month. With insurance that covers it, a manufacturer savings card can drop the copay to ~$25/month. Compounded semaglutide via telehealth runs ~$99–$199/month all-in — though some providers charge a separate membership fee on top of a low headline price. All figures as of June 2026.

Why is semaglutide so expensive?

There is no FDA-approved generic semaglutide in the US — patents run to about 2032 — and Novo Nordisk is currently the sole manufacturer of FDA-approved semaglutide products. High demand since the drug's 2021 weight-management approval, combined with US drug pricing dynamics, keeps retail prices elevated. Manufacturer self-pay programs and compounded options are the main ways people pay less.

Is compounded semaglutide cheaper than Ozempic or Wegovy?

Usually lower on sticker price — compounded semaglutide runs ~$99–$199/month versus ~$349 brand self-pay for Wegovy injectable. Important caveat: compounded semaglutide is not FDA-approved and is not the same as, or therapeutically equivalent to, Wegovy or Ozempic. Some telehealth providers charge a separate monthly membership on top of their drug price; compare the all-in monthly figure before deciding.

How much is semaglutide with insurance?

If your plan covers semaglutide for weight management, a Novo Nordisk manufacturer savings card can bring the copay to as little as $25/month (commercial insurance only). Many plans exclude weight-loss drugs entirely or require prior authorization. The new CMS Medicare Bridge program aims to offer ~$50/month access to eligible Medicare beneficiaries starting July 1, 2026 — verify current eligibility on CMS.gov. Coverage varies widely by plan.

Is there a generic version of semaglutide?

No. There is no FDA-approved generic semaglutide in the US as of 2026, with primary patents running to about 2032. Compounded semaglutide is not a generic — it is a patient-specific preparation made by a licensed 503A compounding pharmacy and is not FDA-approved.

Can I use an FSA or HSA to pay for semaglutide?

Compounded semaglutide, when lawfully prescribed, may be eligible for FSA or HSA reimbursement under IRC §213(d). This is reimbursement-only — you pay out of pocket and submit a receipt; FSA/HSA debit cards generally cannot be used directly at compounding pharmacies. Some plans require a letter of medical necessity. Confirm with your plan administrator and a tax professional before assuming reimbursement. See our full guide: Can you use an HSA or FSA for a GLP-1?

Sources & references

1. Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 2021 (STEP-1 trial of Wegovy/brand semaglutide)
2. FDA. "Human Drug Compounding." U.S. Food & Drug Administration (updated continuously)
3. FDA. "Postmarket Drug Safety Information for Patients and Providers — GLP-1 Receptor Agonists." U.S. Food & Drug Administration
4. NIDDK. "Prescription Medications to Treat Overweight & Obesity." National Institute of Diabetes and Digestive and Kidney Diseases
5. CMS. "CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." Centers for Medicare & Medicaid Services, 2026
6. Wegovy.com / NovoCare. "What to Pay for Wegovy — Self-Pay & Savings Options." Novo Nordisk, June 2026
7. Drugs.com. "Is There a Generic for Ozempic (semaglutide)?" — patent status reference, June 2026
8. GoodRx. "GLP-1 Drugs: Cost and Savings Guide." June 2026
9. Nouri. "GLP-1 Telehealth Pricing 2026 Dataset." Hugging Face, 2026
10. Nouri program pricing and terms — joinnouri.com/becoming (verified June 2026)

Medically reviewed by Amber Patel, MD · Nouri Editorial Team · June 29, 2026. Nouri content is reviewed by licensed clinicians and updated as pricing and guidance change.

Prices and coverage described here reflect publicly available information as of June 2026 and change frequently — verify current figures directly with the manufacturer, your pharmacy, your insurer, and (for HSA/FSA or tax questions) a tax professional before making decisions. This is general information, not medical, financial, or tax advice. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Treatment with compounded GLP-1 medications is prescribed only when clinically appropriate, after review by a U.S.-licensed physician. Not all applicants qualify. Individual results vary.